These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31348046)

  • 1. Activated protein C in neuroprotection and malaria.
    Mosnier LO
    Curr Opin Hematol; 2019 Sep; 26(5):320-330. PubMed ID: 31348046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated protein C, protease activated receptor 1, and neuroprotection.
    Griffin JH; Zlokovic BV; Mosnier LO
    Blood; 2018 Jul; 132(2):159-169. PubMed ID: 29866816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.
    Wang Y; Thiyagarajan M; Chow N; Singh I; Guo H; Davis TP; Zlokovic BV
    Stroke; 2009 May; 40(5):1864-9. PubMed ID: 19057019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity.
    Guo H; Wang Y; Singh I; Liu D; Fernández JA; Griffin JH; Chow N; Zlokovic BV
    J Neurochem; 2009 Apr; 109(1):116-24. PubMed ID: 19166505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities.
    Yamashita A; Zhang Y; Sanner MF; Griffin JH; Mosnier LO
    J Thromb Haemost; 2020 May; 18(5):1027-1038. PubMed ID: 32017367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.
    Griffin JH; Mosnier LO; Fernández JA; Zlokovic BV
    Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2143-2151. PubMed ID: 27758767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.
    Wang Y; Sinha RK; Mosnier LO; Griffin JH; Zlokovic BV
    Blood Cells Mol Dis; 2013 Aug; 51(2):104-8. PubMed ID: 23541526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoprotective-selective activated protein C therapy for ischaemic stroke.
    Mosnier LO; Zlokovic BV; Griffin JH
    Thromb Haemost; 2014 Nov; 112(5):883-92. PubMed ID: 25230930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated protein C.
    Griffin JH; Fernández JA; Gale AJ; Mosnier LO
    J Thromb Haemost; 2007 Jul; 5 Suppl 1():73-80. PubMed ID: 17635713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.
    Bouwens EA; Stavenuiter F; Mosnier LO
    J Thromb Haemost; 2013 Jun; 11 Suppl 1(0 1):242-53. PubMed ID: 23809128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytoprotective protein C pathway.
    Mosnier LO; Zlokovic BV; Griffin JH
    Blood; 2007 Apr; 109(8):3161-72. PubMed ID: 17110453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C.
    Huuskonen MT; Wang Y; Nikolakopoulou AM; Montagne A; Dai Z; Lazic D; Sagare AP; Zhao Z; Fernandez JA; Griffin JH; Zlokovic BV
    J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34846535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice.
    Bir N; Lafargue M; Howard M; Goolaerts A; Roux J; Carles M; Cohen MJ; Iles KE; Fernández JA; Griffin JH; Pittet JF
    Am J Respir Cell Mol Biol; 2011 Sep; 45(3):632-41. PubMed ID: 21257925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.
    Kerschen EJ; Fernandez JA; Cooley BC; Yang XV; Sood R; Mosnier LO; Castellino FJ; Mackman N; Griffin JH; Weiler H
    J Exp Med; 2007 Oct; 204(10):2439-48. PubMed ID: 17893198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.
    Mosnier LO; Zampolli A; Kerschen EJ; Schuepbach RA; Banerjee Y; Fernández JA; Yang XV; Riewald M; Weiler H; Ruggeri ZM; Griffin JH
    Blood; 2009 Jun; 113(23):5970-8. PubMed ID: 19244160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.
    Mosnier LO; Gale AJ; Yegneswaran S; Griffin JH
    Blood; 2004 Sep; 104(6):1740-4. PubMed ID: 15178575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity.
    Guo H; Singh I; Wang Y; Deane R; Barrett T; Fernández JA; Chow N; Griffin JH; Zlokovic BV
    Eur J Neurosci; 2009 Mar; 29(6):1119-30. PubMed ID: 19302148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell painting with an engineered EPCR to augment the protein C system.
    Bouwens EA; Stavenuiter F; Mosnier LO
    Thromb Haemost; 2015 Nov; 114(6):1144-55. PubMed ID: 26272345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated Protein C Strengthens Cardiac Tolerance to Ischemic Insults in Aging.
    Ren D; Fedorova J; Davitt K; Van Le TN; Griffin JH; Liaw PC; Esmon CT; Rezaie AR; Li J
    Circ Res; 2022 Jan; 130(2):252-272. PubMed ID: 34930019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated protein C: biased for translation.
    Griffin JH; Zlokovic BV; Mosnier LO
    Blood; 2015 May; 125(19):2898-907. PubMed ID: 25824691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.